Angiogenesis, the formation of new blood vessels, is a complex and dynamic process
regulated by various pro-and anti-angiogenic molecules, which plays a crucial role in tumor …

Anti-angiogenic therapies (AATs) are used to treat different types of cancers. However, their
success is limited owing to insufficient efficacy and resistance. Recently, single-cell omics …

Anti-angiogenesis therapy, a promising strategy against cancer progression, is limited by
drug-resistance, which could be attributed to changes within the tumor microenvironment …

Prostate cancer (PCa) is one of the most prevalent malignancies in adult males. However,
PCa is resistant to multi-kinase inhibitors-based anti-angiogenic therapies, and the …

Prostate cancer ranks fifth in cancer-related mortality in men worldwide. DNA damage is
implicated in cancer and DNA damage response (DDR) pathways are in place against this …

Breast cancer remains the most common malignant cancer in women, with a staggering
incidence of two million cases annually worldwide; therefore, it is crucial to explore novel …

In recent years, the importance of epigenetic markers in the carcinogenesis of different
malignant neoplasms has been demonstrated, also demonstrating their utility for …

Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer originating from
renal tubular epithelial cells, with clear cell RCC comprising approximately 80% of cases …

Ovarian cancer has become the largest cause of gynaecological cancer-related mortality. It
is typically diagnosed at a late stage and has no effective screening strategy. Ovarian cancer …

Precision medicine has opened up a new era in the development of anti-cancer agents that
is focused on identifying biomarkers predictive of treatment response regardless of tumor …